These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29264713)

  • 1. Subgroup Analysis Stratified by Baseline Pancreatic β-cell Function in a Japanese Study of Dulaglutide in Patients with Type 2 Diabetes.
    Iwamoto N; Matsui A; Kazama H; Oura T
    Diabetes Ther; 2018 Feb; 9(1):383-394. PubMed ID: 29264713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Once Weekly Dulaglutide in East Asian Patients with Type 2 Diabetes: Subgroup Analysis by Potential Influential Factors.
    Ma J; Zhang B; Hou J; Peng Y
    Diabetes Ther; 2021 Jan; 12(1):211-222. PubMed ID: 33161492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies.
    Suzuki S; Oura T; Takeuchi M; Boye KS
    Health Qual Life Outcomes; 2017 Jun; 15(1):123. PubMed ID: 28606095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Once-Weekly Dulaglutide on Glucose Levels in Japanese Patients with Type 2 Diabetes: Findings from a Phase 4, Randomized Controlled Trial.
    Inoue M; Shiramoto M; Oura T; Nasu R; Nakano M; Takeuchi M
    Diabetes Ther; 2019 Jun; 10(3):1019-1027. PubMed ID: 30949907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial.
    Li Q; Zhang Q; Wang R; Hong T
    Diabetes Ther; 2022 Jan; 13(1):161-173. PubMed ID: 34870792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis.
    Patel H; Munir K; Sutherland S; Karanikas CA; Konig M
    Diabetes Ther; 2019 Dec; 10(6):2321-2330. PubMed ID: 31605302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan.
    Onishi Y; Oura T; Matsui A; Matsuura J; Iwamoto N
    Endocr J; 2017 May; 64(5):553-560. PubMed ID: 28367916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen.
    Onishi Y; Ishii H; Oura T; Takeuchi M
    Diabetes Ther; 2020 Mar; 11(3):735-745. PubMed ID: 31994009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Change in HbA
    Gentilella R; Romera I; Nicolay C; Buzzetti R; Vázquez LA; Sesti G
    Diabetes Ther; 2019 Jun; 10(3):1113-1125. PubMed ID: 31055780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-Weekly Dulaglutide with Insulin Therapy for Type 2 Diabetes: Efficacy and Safety Results from a Phase 4, Randomized, Placebo-Controlled Study.
    Ishii H; Onishi Y; Oura T; Takeuchi M
    Diabetes Ther; 2020 Jan; 11(1):133-145. PubMed ID: 31758520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies.
    Kuang J; Zhu J; Liu S; Li Q
    Diabetes Ther; 2020 Oct; 11(10):2329-2339. PubMed ID: 32857293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2).
    Li Y; Li L; De Peng Y; Song GY; Ye SD; Du LY; Hou JN; Ji QH
    Diabetes Ther; 2019 Aug; 10(4):1435-1452. PubMed ID: 31228090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.
    García-Pérez LE; Boye KS; Rosilio M; Jung H; Heitmann E; Norrbacka K; Federici MO; Gentilella R; Guerci B; Giorgino F; Aigner U; Sapin H
    Diabetes Ther; 2021 Jul; 12(7):1929-1946. PubMed ID: 34097244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.
    Gæde P; Johansen P; Tikkanen CK; Pollock RF; Hunt B; Malkin SJP
    Diabetes Ther; 2019 Aug; 10(4):1297-1317. PubMed ID: 31098942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies.
    Morieri ML; Rigato M; Frison V; Simioni N; D'Ambrosio M; Tadiotto F; Paccagnella A; Lapolla A; Avogaro A; Fadini GP
    Metabolism; 2020 May; 106():154190. PubMed ID: 32109448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors.
    Zhou Y; Zhu J; Wu H; Deng Y; Ji Q
    Diabetes Ther; 2021 Oct; 12(10):2677-2690. PubMed ID: 34453682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study.
    Nagaike H; Ohara M; Kohata Y; Hiromura M; Tomoyasu M; Takada M; Yamamoto T; Hayashi T; Fukui T; Hirano T
    Diabetes Ther; 2019 Feb; 10(1):215-228. PubMed ID: 30612316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1.
    Li YM; Zhang LH; Li XJ; Zhang B; Hou JN; Tong NW
    Diabetes Ther; 2020 May; 11(5):1077-1090. PubMed ID: 32219675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes.
    Webb N; Orme M; Witkowski M; Nakanishi R; Langer J
    Diabetes Ther; 2018 Jun; 9(3):973-986. PubMed ID: 29574633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study.
    Ghosal S; Sinha B
    Clin Diabetes Endocrinol; 2018; 4():11. PubMed ID: 29760945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.